Metabolic HealthFDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis
The FDA approved Utebzi (tebipenem pivoxil) on June 17, 2026, for treating complicated urinary tract infections, including pyelonephritis — a kidney infection that often requires hospitalization. Tebipenem pivoxil is an oral carbapenem antibiotic, a class historically available only by intravenous infusion. This approval is significant because it gives clinicians a pill-form option for serious, difficult-to-treat urinary infections caused by drug-resistant gram-negative bacteria. For patients, this could mean avoiding hospital stays or IV infusion centers. For physicians managing antibiotic-resistant infections, it adds a meaningful tool to an increasingly limited arsenal. While not a longevity drug in the traditional sense, chronic or recurrent urinary infections — especially in older adults — carry real morbidity risk, making effective oral treatment options relevant to healthy aging.
